...
首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.
【24h】

Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.

机译:根据甲状腺外延伸程度对甲状腺癌进行分子,形态和结果分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The impact of varying degrees of extrathyroid extension (ETE), especially microscopic ETE (METE), on survival in thyroid carcinomas (TC) has not been well established. Our objective was to analyze ETE at the molecular and histologic levels and assess the effect of its extent on outcome. METHODS: All cases of TC with ETE but without nodal metastases at presentation (NMP) were identified over a 20-year period and grouped into gross and METE. Twelve papillary thyroid carcinomas (PTCs) without ETE and NMP were also analyzed. Cases with paraffin tissues were subjected to mass spectrometry genotyping encompassing the most significant oncogenes in TC: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, and AKT1, and other related genes were surveyed. RESULTS: Eighty-one (10%) of 829 patients in the database had ETE and no NMP. There was a much higher frequency of poorly differentiated and anaplastic carcinomas (12/29, 41%) in patients with gross ETE than in those with METE (3/52, 6%) (p < 0.01). There was a higher disease-specific survival (DSS) in patients with METE than in those with gross ETE (p < 0.0001). Except for an anaplastic case, no recurrences were detected in 45 patients with METE, including 23 PTC patients followed up for a median of 10 years without radioactive iodine therapy. Within patients with gross invasion into trachea/esophagus, tumors with high mitotic activity and/or tumor necrosis correlated with worse DSS (p < 0.05). Fifty-six cases with ETE were genotyped as follows: BRAFV600E, 39 (70%); BRAFV600E-AKT1, 1 (1.8%); NRAS, 1 (1.8%); KRAS, 1 (1.8%); RET/PTC, 3 (5%); wild type, 11 (19.6%). Within PTCs, BRAF positivity rate increased the risk of ETE (p = 0.01). If PTC follicular variants are excluded, BRAF positivity does not correlate with ETE status within classical/tall cell PTC. CONCLUSION: (i) PTCs with METE without NMP have an extremely low recurrence rate in contrast to tumors with gross ETE. (ii) High mitotic activity and/or tumor necrosis confers worse DSS even in patients stratified for gross ETE in trachea/esophagus. (iii) BRAF positivity correlates with the presence of ETE in PTC, but this relationship is lost within classical/tall cell PTC if follicular variants are excluded from the analysis.
机译:背景:尚未明确建立不同程度的甲状腺外扩张(ETE),尤其是微观ETE(METE)对甲状腺癌(TC)生存的影响。我们的目标是在分子水平和组织学水平上分析ETE,并评估其程度对预后的影响。方法:在20年的期间内,确定了所有伴有ETE但无淋巴结转移的TC病例(NMP),并分为总和METE。还分析了十二个没有ETE和NMP的甲状腺乳头状癌(PTC)。对具有石蜡组织的病例进行了质谱分型,该分型包括TC中最重要的致癌基因:对RET,BRAF,NRAS,HRAS,KRAS,PIK3CA和AKT1中的111个突变进行了调查,并调查了其他相关基因。结果:数据库中的829例患者中有81例(10%)有ETE而无NMP。大体ETE患者中低分化和间变性癌的发生率(12/29,41%)比METE患者(3/52,6%)高得多(p <0.01)。 METE患者的疾病特异性生存率(DSS)高于总ETE患者(p <0.0001)。除间变性病例外,未检出复发的45例METE患者,包括23例PTC患者,随访10年,未进行放射性碘治疗。在严重侵入气管/食道的患者中,有丝分裂活性高和/或肿瘤坏死的肿瘤与较差的DSS相关(p <0.05)。 56例ETE患者的基因型如下:BRAFV600E,39(70%); BRAFV600E-AKT1,1(1.8%); NRAS,1(1.8%); KRAS,1(1.8%); RET / PTC,3(5%);野生型11(19.6%)。在PTC中,BRAF阳性率增加了ETE的风险(p = 0.01)。如果排除PTC卵泡变异,BRAF阳性与经典/高细胞PTC中的ETE状态不相关。结论:(i)伴有NTE的METE的PTC的复发率极低,而伴有总ETE的肿瘤。 (ii)即使在因气管/食道总ETE分层的患者中,高有丝分裂活性和/或肿瘤坏死也使DSS恶化。 (iii)BRAF阳性与PTC中ETE的存在相关,但是如果从分析中排除卵泡变异,则在经典/高细胞PTC中这种关系会丢失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号